10 research outputs found
In vitro reactivation of latent HIV-1 by cytostatic bis (thiosemicarbazonate) gold(III) complexes
BACKGROUND : A number of cytostatic agents have been investigated for the ability to reactivate latent viral
reservoirs, which is a major prerequisite for the eradication of HIV-1 infection. Two cytostatic bis(thiosemicarbazonate)
gold(III) complexes (designated 1 and 2) were tested for this potential in the U1 latency model of HIV-1 infection.
METHODS : Cell viability in the presence or absence of 1 and 2 was determined using a tetrazolium dye and evidence of
reactivation was assessed by p24 antigen capture following exposure to a latency stimulant, phorbol myristate acetate
(PMA) and or test compounds. The latency reactivation mechanism was explored by determining the effect of the
complexes on protein kinase C (PKC), histone deacetylases (HDAC) and proinflammatory cytokine production.
RESULTS : The CC50 of the complexes in U1 cells were 0.53 ± 0.12 ΌM for 1 and 1.0 ± 0.4 ΌM for 2. In the absence of PMA
and at non toxic concentrations of 0.2 and 0.5 ΌM, 1 and 2 significantly (p †0.02) reactivated virus in U1 cells by 2.7
and 2.3 fold respectively. In comparison, a 2.6 fold increase (p = 0.03) in viral reactivation was observed for hydroxyurea
(HU), which was used as a cytostatic and latent HIV reactivation control. Viral reactivation was absent for the complexes
during co-stimulation with PMA indicating the lack of an additive effect between the chemicals as well as an absence
of inhibition of PMA induced HIV reactivation but for HU inhibition of the stimulantâs activity was observed (p = 0.01).
Complex 1 and 2 activated PKC activity by up to 32% (p < 0.05) but no significant inhibition of HDAC was observed.
Increases in TNF-α levels suggested that the reactivation of virus by the complexes may have been due to contributions
from the latter and the activation of PKC.
CONCLUSION : The ethyl group structural difference between 1 and 2 seems to influence bioactivity with lower active
concentrations of 1, suggesting that further structural modifications should improve specificity. The cytostatic effect of 1
and 2 and now HIV reactivation from a U1 latency model is consistent with that of the cytostatic agent, HU. These
findings suggest that the complexes have a potential dual (cytostatic and reactivation) role in viral âactivation/eliminationâ.AuTEK Biomed (Mintek and Harmony Gold),Technology Innovation Agency (TIA) and the University of Pretoria.http://www.biomedcentral.com/bmcinfectdis/hb201
Chloroquine and beyond:exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS
The restoration of the immune system prompted by antiretroviral therapy (ART) has allowed drastically reducing the mortality and morbidity of HIV infection. However, one main source of clinical concern is the persistence of immune hyperactivation in individuals under ART. Chronically enhanced levels of T-cell activation are associated with several deleterious effects which lead to faster disease progression and slower CD4(+) T-cell recovery during ART. In this article, we discuss the rationale, and review the results, of the use of antimalarial quinolines, such as chloroquine and its derivative hydroxychloroquine, to counteract immune activation in HIV infection. Despite the promising results of several pilot trials, the most recent clinical data indicate that antimalarial quinolines are unlikely to exert a marked beneficial effect on immune activation. Alternative approaches will likely be required to reproducibly decrease immune activation in the setting of HIV infection. If the quinoline-based strategies should nevertheless be pursued in future studies, particular care must be devoted to the dosage selection, in order to maximize the chances to obtain effective in vivo drug concentrations
A cure for AIDS:a matter of timing?
Despite the huge clinical success of antiretroviral therapy, several factors such as side effects, requirement of life-long adherence, high cost, incomplete access to therapies and development of drug resistance make the quest for an ultimate cure of HIV/AIDS a worldwide priority of biomedical research. In this respect, several sterilizing or functional cures have been reported in the last years in both non-human primates and humans. This review provides a summary of the main results achieved so far, outlining their strengths as well as their limitations. A synthetic interpretation of these results could be pivotal in order to develop an effective and widely available cure